title: Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
abstract: Traditional disease-modifying antirheumatic drugs (DMARD) remain the first-line treatment of psoriatic arthritis (PsA), despite lack of randomized controlled trials, and with evidence based on observational studies. Anti-tumor necrosis factor agents remain a top choice for biologic treatment, complemented with new biologics with different targets (IL12-23 and IL17). Unmet needs have been identified for patients who do not respond to treatment. Among targeted small molecules Apremilast is approved for the treatment of PsA and Tofactitinib is under investigation. The drugs discussed herein have the potential to address unmet needs; however, additional research is required to identify more effective therapies for PsA.
authors.affiliation: Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario, y Fundcion PM. Catoggio, Peron 4190, Buenos Aires (1181) CABA, Argentina. Electronic address: enrique.soriano@hospitalitaliano.org.ar.
authors.forename: Enrique R
authors.initials: ER
authors.lastname: Soriano
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000378:metabolism; D019468:Disease Management; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; C505730:apremilast
keywords: Psoriatic arthritis; Small molecules; Traditional disease-modifying antirheumatic drugs; Treatment psoriatic arthritis